Asia-Pacific Biologics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Asia-Pacific biologics market is projected to register a substantial CAGR of 11.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Asia-Pacific Biologics Market, By Class (Tumor Necrosis Factor-A (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (mAbs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Other Products), Route of Administration (Injection, Infusion, and Others), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insect Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Taiwan, New Zealand, and Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific biologics market are:

Rising prevalence of chronic diseases such as diabetes and cancers

Recent advancements in biologics

Changes in lifestyle

Market Players

The major companies which are dealing in the Asia-Pacific biologics market are listed below:

AbbVie Inc.

AGC Biologics

BeiGene

Bharat Biotech

BioDiem

Biogen

Biocon

Bristol-Myers Squibb Company

Catalent, Inc.

Celltrion Healthcare Co., Ltd.

CHIME BIOLOGICS

Cipla Inc.

F. Hoffman-La Roche Ltd

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.

GlaxoSmithKline plc.

Innovent

Intas Pharmaceutical Ltd.

Ipsen Pharma

Johnson & Johnson Services, Inc.

KM Biologics

MERCK & CO., INC.

NBHL ltd.

Panacea Biotec

Pfizer Inc.

Qilu Pharmaceutical Co., Ltd.

Serum Institute of India Pvt. Ltd.

Shanghai Henlius Biotech, Inc.

Teva Pharmaceutical Industries Ltd.

WuXi Biologics

YL Biologics

1 INTRODUCTION 22

1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF ASIA-PACIFIC BIOLOGICS MARKET 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24

2 MARKET SEGMENTATION 27

2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 CLASS LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 MARKET APPLICATION COVERAGE GRID 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37

3 EXECUTIVE SUMMARY 38

4 PREMIUM INSIGHTS 41

4.1 PESTEL ANALYSIS 42
4.2 PORTER'S FIVE FORCES 43

5 INDUSTRY INSIGHTS 44

5.1 KEY PRICING STRATEGIES 44
5.2 KEY PATIENT ENROLLMENT STRATEGIES 44

6 MERGERS AND ACQUISITIONS BY KEY MARKET PLAYERS 45

7 ASIA-PACIFIC BIOLOGICS MARKET: LAWS AND REGULATIONS 47

8 MARKET OVERVIEW 53

8.1 DRIVERS 55
- 8.1.1 RISING PREVALENCE OF CHRONIC DISEASES SUCH AS DIABETES AND CANCERS 55
- 8.1.2 CHANGES IN LIFESTYLE 56
- 8.1.3 RECENT ADVANCEMENTS IN BIOLOGICS 56
8.2 RESTRAINTS 57
- 8.2.1 COMPLEX MANUFACTURING PROCESS OF BIOLOGICS 57
- 8.2.2 ADVERSE SIDE-EFFECTS OF BIOLOGICS 57
8.3 OPPORTUNITIES 59
- 8.3.1 RISING HEALTHCARE EXPENSES 59
- 8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 59
- 8.3.3 SURGE IN HEALTHCARE EXPENDITURE 60
- 8.3.4 GROWING NUMBER OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING COMPANIES IN ASIA 61
8.4 CHALLENGE 61
- 8.4.1 STRINGENT REGULATORY POLICIES 61

9 ASIA-PACIFIC BIOLOGICS MARKET, BY CLASS 63

9.1 OVERVIEW 64
9.2 TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS 67
- 9.2.1 ADALIMUMAB 68
- 9.2.2 CERTOLIZUMAB 68
- 9.2.3 ETANERCEPT 68
- 9.2.4 INFLIXIMAB 68
- 9.2.5 OTHERS 68
9.3 B-CELL INHIBITORS 68
- 9.3.1 BELIMUMAB 69
- 9.3.2 RITUXIMAB 69
- 9.3.3 OTHERS 69
9.4 INTERLEUKIN INHIBITORS 69
- 9.4.1 ANAKINRA 70
- 9.4.2 CANAKINUMAB 70
- 9.4.3 IXEKIZUMAB 70
- 9.4.4 SECUKINUMAB 70
- 9.4.5 TOCILIZUMAB 70
- 9.4.6 USTEKINUMAB 70
- 9.4.7 OTHERS 70
9.5 SELECTIVE CO-STIMULATION MODULATORS (ABATACEPT) 71
9.6 OTHERS 71

10 ASIA-PACIFIC BIOLOGICS MARKET, BY TYPE 72

10.1 OVERVIEW 73
10.2 MONOCLONAL ANTIBODIES (MABS) 75
- 10.2.1 ANTI-CANCER MABS 76
- 10.2.2 IMMUNOLOGICAL MABS 76
- 10.2.3 ANTI-INFECTIVE MONOCLONAL ANTIBODIES (MABS) 76
- 10.2.4 CARDIOVASCULAR AND CEREBROVASCULAR MABS 77
- 10.2.5 NEUROPHARMACOLOGICAL MABS 77
- 10.2.6 OTHERS MABS 77
10.3 THERAPEUTIC PROTEINS 77
- 10.3.1 METABOLIC DISORDERS THERAPEUTIC PROTEINS 78
- 10.3.2 CANCER THERAPEUTIC PROTEINS 78
- 10.3.3 CARDIOVASCULAR THERAPEUTIC PROTEINS 78
- 10.3.4 IMMUNOLOGICAL THERAPEUTIC PROTEINS 78
- 10.3.5 OTHERS THERAPEUTIC PROTEINS 78
10.4 VACCINES 78
- 10.4.1 ANTI-INFECTIVE VACCINES 79
- 10.4.2 AUTOIMMUNITY VACCINES 79
- 10.4.3 OTHERS 79
10.5 CELLULAR BASED BIOLOGICS 79
10.6 GENE BASED BIOLOGICS 80
10.7 OTHERS 81

11 ASIA-PACIFIC BIOLOGICS MARKET, BY APPLICATION 82

11.1 OVERVIEW 83
11.2 ONCOLOGY 85
- 11.2.1 BREAST CANCER 86
- 11.2.2 LEUKEMIA 86
- 11.2.3 OVARIAN CANCER 86
- 11.2.4 NON-HODGKIN LYMPHOMA 86
- 11.2.5 PROSTATE CANCER 87
- 11.2.6 COLORECTAL CANCER 87
- 11.2.7 OTHERS 87
  - 11.2.7.1 BLADDER CANCER 87
  - 11.2.7.2 LUNG CANCER 87
11.3 AUTOIMMUNE DISEASES 87
- 11.3.1 SYSTEMIC SCLEROSIS 88
- 11.3.2 CROHN'S DISEASE 88
- 11.3.3 RHEUMATOID ARTHRITIS 88
- 11.3.4 SYSTEMIC LUPUS ERYTHEMATOUS 88
- 11.3.5 OTHERS 88
  - 11.3.5.1 SJOGREN'S SYNDROME 89
  - 11.3.5.2 MULTIPLE SCLEROSIS 89
  - 11.3.5.3 PERNICIOUS ANEMIA 89
  - 11.3.5.4 OTHERS 89
11.4 DIABETES 89
11.5 INFECTIOUS DISEASES 90
11.6 CARDIOVASCULAR DISEASES 90
11.7 OPHTHALMIC CONDITIONS 90
11.8 DERMATOLOGICAL DISEASES 91
11.9 OTHERS 92

12 ASIA-PACIFIC BIOLOGICS MARKET, BY SOURCE MATERIAL 93

12.1 OVERVIEW 94
12.2 HUMANS 98
12.3 AVIAN CELL CULTURE 98
12.4 YEAST 98
12.5 BACTERIA 99
12.6 INSECTS CELL CULTURE 99
12.7 TRANSGENICS 99
12.8 OTHERS 100

13 ASIA-PACIFIC BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION 101

13.1 OVERVIEW 102
13.2 INJECTION 105
13.3 INFUSION 105

14 ASIA-PACIFIC BIOLOGICS MARKET, BY END USER 106

14.1 OVERVIEW 107
14.2 HOSPITALS 109
14.3 SPECIALTY CLINICS 110
14.4 ACADEMICS AND RESEARCH INSTITUTES 110
14.5 OTHERS 111

15 ASIA-PACIFIC BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL 112

15.1 OVERVIEW 113
15.2 DIRECT TENDER 115
15.3 RETAIL SALES 116
15.4 THIRD PARTY DISTRIBUTION 116

16 ASIA-PACIFIC BIOLOGICS MARKET, BY COUNTRY 117

16.1 CHINA 122
16.2 JAPAN 127
16.3 INDIA 133
16.4 AUSTRALIA 139
16.5 SOUTH KOREA 144
16.6 SINGAPORE 149
16.7 MALAYSIA 154
16.8 INDONESIA 159
16.9 THAILAND 164
16.10 PHILIPPINES 169
16.11 VIETNAM 174
16.12 REST OF ASIA-PACIFIC 179

17 ASIA-PACIFIC BIOLOGICS MARKET: COMPANY LANDSCAPE 180

17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 180

18 SWOT ANALYSIS 181

19 COMPANY PROFILE 182

19.1 PFIZER INC. 182
- 19.1.1 COMPANY SNAPSHOT 182
- 19.1.2 REVENUE ANALYSIS 183
- 19.1.3 PRODUCT PORTFOLIO 183
- 19.1.4 RECENT DEVELOPMENT 183
- 19.1.5 MERGER 184
19.2 F. HOFFMANN-LA ROCHE LTD 185
- 19.2.1 COMPANY SNAPSHOT 185
- 19.2.2 REVENUE ANALYSIS 185
- 19.2.3 PRODUCT PORTFOLIO 186
- 19.2.4 RECENT DEVELOPMENT 186
19.3 BRISTOL-MEYERS SQUIBB COMPANY 187
- 19.3.1 COMPANY SNAPSHOT 187
- 19.3.2 REVENUE ANALYSIS 187
- 19.3.3 PRODUCT PORTFOLIO 188
- 19.3.4 RECENT DEVELOPMENT 188
19.4 GLAXOSMITHKLINE PLC 189
- 19.4.1 COMPANY SNAPSHOT 189
- 19.4.2 REVENUE ANALYSIS 189
- 19.4.3 PRODUCT PORTFOLIO 190
- 19.4.4 RECENT DEVELOPMENT 190
19.5 TEVA PHARMACEUTICAL INDUSTRIES LTD 191
- 19.5.1 COMPANY SNAPSHOT 191
- 19.5.2 REVENUE ANALYSIS 191
- 19.5.3 PRODUCT PORTFOLIO 192
- 19.5.4 RECENT DEVELOPMENT 192
- 19.5.5 EXPANSION 192
19.6 ABBVIE INC. 193
- 19.6.1 COMPANY SNAPSHOT 193
- 19.6.2 REVENUE ANALYSIS 193
- 19.6.3 PRODUCT PORTFOLIO 194
- 19.6.4 RECENT DEVELOPMENT 194
  - 19.6.4.1 FDA APPROVAL 194
19.7 AGC BIOLOGICS 195
- 19.7.1 COMPANY SNAPSHOT 195
- 19.7.2 PRODUCT PORTFOLIO 195
- 19.7.3 RECENT DEVELOPMENTS 195
19.8 BIODIEM 196
- 19.8.1 COMPANY SNAPSHOT 196
- 19.8.2 REVENUE ANALYSIS 196
- 19.8.3 PRODUCT PORTFOLIO 197
- 19.8.4 RECENT DEVELOPMENT 197
19.9 BEIGENE 198
- 19.9.1 COMPANY SNAPSHOT 198
- 19.9.2 REVENUE ANALYSIS 198
- 19.9.3 PRODUCT PORTFOLIO 199
- 19.9.4 RECENT DEVELOPMENTS 199
19.10 BIOCON 201
- 19.10.1 COMPANY SNAPSHOT 201
- 19.10.2 REVENUE ANALYSIS 201
- 19.10.3 PRODUCT PORTFOLIO 202
- 19.10.4 RECENT DEVELOPMENTS 203
19.11 BIOGEN 204
- 19.11.1 COMPANY SNAPSHOT 204
- 19.11.2 REVENUE ANALYSIS 204
- 19.11.3 PRODUCT PORTFOLIO 205
- 19.11.4 RECENT DEVELOPMENTS 205
19.12 BHARAT BIOTECH 206
- 19.12.1 COMPANY SNAPSHOT 206
- 19.12.2 PRODUCT PORTFOLIO 206
- 19.12.3 RECENT DEVELOPMENTS 207
19.13 CATALENT, INC. 208
- 19.13.1 COMPANY SNAPSHOT 208
- 19.13.2 REVENUE ANALYSIS 208
- 19.13.3 PRODUCT PORTFOLIO 209
- 19.13.4 RECENT DEVELOPMENTS 209
19.14 CHIME BIOLOGICS 210
- 19.14.1 COMPANY SNAPSHOT 210
- 19.14.2 PRODUCT PORTFOLIO 210
- 19.14.3 RECENT DEVELOPMENTS 210
19.15 CIPLA INC. 211
- 19.15.1 COMPANY SNAPSHOT 211
- 19.15.2 REVENUE ANALYSIS 211
- 19.15.3 PRODUCT PORTFOLIO 212
- 19.15.4 RECENT DEVELOPMENTS 212
19.16 CELLTRION HEALTHCARE CO.,LTD. 213
- 19.16.1 COMPANY SNAPSHOT 213
- 19.16.2 REVENUE ANALYSIS 213
- 19.16.3 PRODUCT PORTFOLIO 214
- 19.16.4 RECENT DEVELOPMENT 214
19.17 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD. 215
- 19.17.1 COMPANY SNAPSHOT 215
- 19.17.2 REVENUE ANALYSIS 215
- 19.17.3 PRODUCT PORTFOLIO 216
- 19.17.4 RECENT DEVELOPMENTS 216
19.18 INNOVENT 217
- 19.18.1 COMPANY SNAPSHOT 217
- 19.18.2 REVENUE ANALYSIS 217
- 19.18.3 PRODUCT PORTFOLIO 218
- 19.18.4 RECENT DEVELOPMENT 219
19.19 IPSEN PHARMA 220
- 19.19.1 COMPANY SNAPSHOT 220
- 19.19.2 REVENUE ANALYSIS 220
- 19.19.3 PRODUCT PORTFOLIO 221
- 19.19.4 RECENT DEVELOPMENT 221

19.20 INTAS PHARMACEUTICAL LTD. 222
- 19.20.1 COMPANY SNAPSHOT 222
- 19.20.2 PRODUCT PORTFOLIO 223
- 19.20.3 RECENT DEVELOPMENT 223
19.21 JOHNSON & JOHNSON SERVICES, INC. 224
- 19.21.1 COMPANY SNAPSHOT 224
- 19.21.2 REVENUE ANALYSIS 224
- 19.21.3 PRODUCT PORTFOLIO 225
- 19.21.4 RECENT DEVELOPMENT 225
19.22 KM BIOLOGICS (A SUBSIDIARY OF MEIJI HOLDINGS CO., LTD.) 226
- 19.22.1 COMPANY SNAPSHOT 226
- 19.22.2 REVENUE ANALYSIS 226
- 19.22.3 PRODUCT PORTFOLIO 227
- 19.22.4 RECENT DEVELOPMENT 227
19.23 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC. 228
- 19.23.1 COMPANY SNAPSHOT 228
- 19.23.2 REVENUE ANALYSIS 228
- 19.23.3 PRODUCT PORTFOLIO 229
- 19.23.4 RECENT DEVELOPMENTS 229
19.24 NBHL LTD. 231
- 19.24.1 COMPANY SNAPSHOT 231
- 19.24.2 PRODUCT PORTFOLIO 231
- 19.24.3 RECENT DEVELOPMENT 231
19.25 PANACEA BIOTEC 232
- 19.25.1 COMPANY SNAPSHOT 232
- 19.25.2 REVENUE ANALYSIS 232
- 19.25.3 PRODUCT PORTFOLIO 233
- 19.25.4 RECENT DEVELOPMENT 233
19.26 QILU PHARMACEUTICAL CO., LTD. 234
- 19.26.1 COMPANY SNAPSHOT 234
- 19.26.2 PRODUCT PORTFOLIO 234
- 19.26.3 RECENT DEVELOPMENT 234
19.27 SERUM INSTITUTE OF INDIA PVT. LTD. 235
- 19.27.1 COMPANY SNAPSHOT 235
- 19.27.2 PRODUCT PORTFOLIO 235
- 19.27.3 RECENT DEVELOPMENTS 237
19.28 SHANGHAI HENLIUS BIOTECH, INC. (2022) 238
- 19.28.1 COMPANY SNAPSHOT 238
- 19.28.2 REVENUE ANALYSIS 238
- 19.28.3 PRODUCT PORTFOLIO 239
- 19.28.4 RECENT DEVELOPMENTS 240
19.29 SHANGHAI HENLIUS BIOTECH, INC. (2022) 241
- 19.29.1 COMPANY SNAPSHOT 241
- 19.29.2 REVENUE ANALYSIS 241
- 19.29.3 PRODUCT PORTFOLIO 242
- 19.29.4 RECENT DEVELOPMENTS 243
19.30 YL BIOLOGICS 244
- 19.30.1 COMPANY SNAPSHOT 244
- 19.30.2 PRODUCT PORTFOLIO 244
- 19.30.3 RECENT DEVELOPMENT 244

20 QUESTIONNAIRE 245

21 RELATED REPORTS 248

LIST OF TABLES

TABLE 1 REGULATIONS IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT COUNTRIES 47
TABLE 2 ASIA-PACIFIC BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 66
TABLE 3 ASIA-PACIFIC TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 67
TABLE 4 ASIA-PACIFIC B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 69
TABLE 5 ASIA-PACIFIC INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 70
TABLE 6 ASIA-PACIFIC BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 75
TABLE 7 ASIA-PACIFIC MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 76
TABLE 8 ASIA-PACIFIC THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 78
TABLE 9 ASIA-PACIFIC VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 79
TABLE 10 ASIA-PACIFIC BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 85
TABLE 11 ASIA-PACIFIC ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 86
TABLE 12 ASIA-PACIFIC OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 87
TABLE 13 ASIA-PACIFIC AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 88
TABLE 14 ASIA-PACIFIC OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 89
TABLE 15 ASIA-PACIFIC BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 97
TABLE 16 ASIA-PACIFIC BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 104
TABLE 17 ASIA-PACIFIC BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 109
TABLE 18 ASIA-PACIFIC BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 115
TABLE 19 ASIA-PACIFIC BIOLOGICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 121
TABLE 20 CHINA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 122
TABLE 21 CHINA TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 122
TABLE 22 CHINA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 122
TABLE 23 CHINA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 123
TABLE 24 CHINA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
TABLE 25 CHINA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
TABLE 26 CHINA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
TABLE 27 CHINA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
TABLE 28 CHINA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 124
TABLE 29 CHINA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 124
TABLE 30 CHINA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 125
TABLE 31 CHINA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 125
TABLE 32 CHINA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 125
TABLE 33 CHINA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 126
TABLE 34 CHINA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 126
TABLE 35 CHINA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 126
TABLE 36 CHINA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 126
TABLE 37 JAPAN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 127
TABLE 38 JAPAN TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 127
TABLE 39 JAPAN B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 127
TABLE 40 JAPAN INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 128
TABLE 41 JAPAN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
TABLE 42 JAPAN MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
TABLE 43 JAPAN THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 44 JAPAN VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 45 JAPAN BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 129
TABLE 46 JAPAN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
TABLE 47 JAPAN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 48 JAPAN OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 49 JAPAN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 50 JAPAN OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 132
TABLE 51 JAPAN BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 132
TABLE 52 JAPAN BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 132
TABLE 53 JAPAN BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 132
TABLE 54 INDIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 133
TABLE 55 INDIA TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 133
TABLE 56 INDIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 133
TABLE 57 INDIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 134
TABLE 58 INDIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
TABLE 59 INDIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
TABLE 60 INDIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 135
TABLE 61 INDIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 135
TABLE 62 INDIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 135
TABLE 63 INDIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 135
TABLE 64 INDIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 137
TABLE 65 INDIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 137
TABLE 66 INDIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 137
TABLE 67 INDIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 138
TABLE 68 INDIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 138
TABLE 69 INDIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 138
TABLE 70 INDIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 138
TABLE 71 AUSTRALIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 139
TABLE 72 AUSTRALIA TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 139
TABLE 73 AUSTRALIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 139
TABLE 74 AUSTRALIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 140
TABLE 75 AUSTRALIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 140
TABLE 76 AUSTRALIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 140
TABLE 77 AUSTRALIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 141
TABLE 78 AUSTRALIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 141
TABLE 79 AUSTRALIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 141
TABLE 80 AUSTRALIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 141
TABLE 81 AUSTRALIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 142
TABLE 82 AUSTRALIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 142
TABLE 83 AUSTRALIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 142
TABLE 84 AUSTRALIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 143
TABLE 85 AUSTRALIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 143
TABLE 86 AUSTRALIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 143
TABLE 87 AUSTRALIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 143
TABLE 88 SOUTH KOREA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 144
TABLE 89 SOUTH KOREA TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 144
TABLE 90 SOUTH KOREA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 144
TABLE 91 SOUTH KOREA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 145
TABLE 92 SOUTH KOREA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
TABLE 93 SOUTH KOREA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
TABLE 94 SOUTH KOREA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 146
TABLE 95 SOUTH KOREA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 146
TABLE 96 SOUTH KOREA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 146
TABLE 97 SOUTH KOREA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 146
TABLE 98 SOUTH KOREA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 147
TABLE 99 SOUTH KOREA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 147
TABLE 100 SOUTH KOREA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 147
TABLE 101 SOUTH KOREA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 148
TABLE 102 SOUTH KOREA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 148
TABLE 103 SOUTH KOREA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 148
TABLE 104 SOUTH KOREA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 148
TABLE 105 SINGAPORE BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 149
TABLE 106 SINGAPORE TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 149
TABLE 107 SINGAPORE B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 149
TABLE 108 SINGAPORE INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 150
TABLE 109 SINGAPORE BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 110 SINGAPORE MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 111 SINGAPORE THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
TABLE 112 SINGAPORE VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
TABLE 113 SINGAPORE BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 151
TABLE 114 SINGAPORE BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 151
TABLE 115 SINGAPORE ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 152
TABLE 116 SINGAPORE OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 152
TABLE 117 SINGAPORE AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 152
TABLE 118 SINGAPORE OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 153
TABLE 119 SINGAPORE BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 153
TABLE 120 SINGAPORE BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 153
TABLE 121 SINGAPORE BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 153
TABLE 122 MALAYSIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 154
TABLE 123 MALAYSIA TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 154
TABLE 124 MALAYSIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 154
TABLE 125 MALAYSIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 155
TABLE 126 MALAYSIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 155
TABLE 127 MALAYSIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 155
TABLE 128 MALAYSIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 156
TABLE 129 MALAYSIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 156
TABLE 130 MALAYSIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 156
TABLE 131 MALAYSIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 156
TABLE 132 MALAYSIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 157
TABLE 133 MALAYSIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 157
TABLE 134 MALAYSIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 157
TABLE 135 MALAYSIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 158
TABLE 136 MALAYSIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 158
TABLE 137 MALAYSIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 158
TABLE 138 MALAYSIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 158
TABLE 139 INDONESIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 159
TABLE 140 INDONESIA TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 159
TABLE 141 INDONESIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 159
TABLE 142 INDONESIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 160
TABLE 143 INDONESIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 160
TABLE 144 INDONESIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 160
TABLE 145 INDONESIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 161
TABLE 146 INDONESIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 161
TABLE 147 INDONESIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 161
TABLE 148 INDONESIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 161
TABLE 149 INDONESIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 162
TABLE 150 INDONESIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 162
TABLE 151 INDONESIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 162
TABLE 152 INDONESIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 163
TABLE 153 INDONESIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 163
TABLE 154 INDONESIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 163
TABLE 155 INDONESIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 163
TABLE 156 THAILAND BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 164
TABLE 157 THAILAND TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 164
TABLE 158 THAILAND B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 164
TABLE 159 THAILAND INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 165
TABLE 160 THAILAND BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
TABLE 161 THAILAND MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
TABLE 162 THAILAND THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
TABLE 163 THAILAND VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
TABLE 164 THAILAND BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 166
TABLE 165 THAILAND BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
TABLE 166 THAILAND ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 167 THAILAND OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 168 THAILAND AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 169 THAILAND OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 168
TABLE 170 THAILAND BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION) 168
TABLE 171 THAILAND BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION) 168
TABLE 172 THAILAND BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 168
TABLE 173 PHILIPPINES BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 169
TABLE 174 PHILIPPINES TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 169
TABLE 175 PHILIPPINES B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 169
TABLE 176 PHILIPPINES INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION) 170
TABLE 177 PHILIPPINES BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
TABLE 178 PHILIPPINES MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 170

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC BIOLOGICS MARKET: SEGMENTATION 27
FIGURE 2 ASIA-PACIFIC BIOLOGICS MARKET: DATA TRIANGULATION 29
FIGURE 3 ASIA-PACIFIC BIOLOGICS MARKET: DROC ANALYSIS 30
FIGURE 4 ASIA-PACIFIC BIOLOGICS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 31
FIGURE 5 ASIA-PACIFIC BIOLOGICS MARKET : COMPANY RESEARCH ANALYSIS 31
FIGURE 6 ASIA-PACIFIC BIOLOGICS MARKET: MULTIVARIATE MODELLING 32
FIGURE 7 ASIA-PACIFIC BIOLOGICS MARKET: INTERVIEW DEMOGRAPHICS 33
FIGURE 8 ASIA-PACIFIC BIOLOGICS MARKET: DBMR MARKET POSITION GRID 34
FIGURE 9 ASIA-PACIFIC BIOLOGICS MARKET: VENDOR SHARE ANALYSIS 35
FIGURE 10 ASIA-PACIFIC BIOLOGICS MARKET: APPLICATION TYPE COVERAGE GRID 36
FIGURE 11 ASIA-PACIFIC BIOLOGICS MARKET: SEGMENTATION 40
FIGURE 12 AN INCREASE IN THE PREVALENCE OF CHRONIC DISEASES SUCH AS DIABETES AND CANCER AND RECENT ADVANCEMENTS IN BIOLOGICS ARE EXPECTED TO DRIVE THE ASIA-PACIFIC BIOLOGICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 41
FIGURE 13 TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC BIOLOGICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 41
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC BIOLOGICS MARKET 54
FIGURE 15 ASIA-PACIFIC BIOLOGICS MARKET: BY CLASS, 2022 64
FIGURE 16 ASIA-PACIFIC BIOLOGICS MARKET: BY CLASS, 2023-2030 (USD MILLION) 65
FIGURE 17 ASIA-PACIFIC BIOLOGICS MARKET: BY CLASS, CAGR (2023-2030) 65
FIGURE 18 ASIA-PACIFIC BIOLOGICS MARKET: BY CLASS, LIFELINE CURVE 66
FIGURE 19 ASIA-PACIFIC BIOLOGICS MARKET: BY TYPE, 2022 73
FIGURE 20 ASIA-PACIFIC BIOLOGICS MARKET: BY TYPE, 2023-2030 (USD MILLION) 74
FIGURE 21 ASIA-PACIFIC BIOLOGICS MARKET: BY TYPE, CAGR (2023-2030) 74
FIGURE 22 ASIA-PACIFIC BIOLOGICS MARKET: BY TYPE, LIFELINE CURVE 75
FIGURE 23 ASIA-PACIFIC BIOLOGICS MARKET: BY APPLICATION, 2022 83
FIGURE 24 ASIA-PACIFIC BIOLOGICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 84
FIGURE 25 ASIA-PACIFIC BIOLOGICS MARKET: BY APPLICATION, CAGR (2023-2030) 84
FIGURE 26 ASIA-PACIFIC BIOLOGICS MARKET: BY APPLICATION, LIFELINE CURVE 85
FIGURE 27 ASIA-PACIFIC BIOLOGICS MARKET: BY SOURCE MATERIAL, 2022 94
FIGURE 28 ASIA-PACIFIC BIOLOGICS MARKET: BY SOURCE MATERIAL, 2023-2030 (USD MILLION) 95
FIGURE 29 ASIA-PACIFIC BIOLOGICS MARKET: BY SOURCE MATERIAL, CAGR (2023-2030) 96
FIGURE 30 ASIA-PACIFIC BIOLOGICS MARKET: BY SOURCE MATERIAL, LIFELINE CURVE 97
FIGURE 31 ASIA-PACIFIC BIOLOGICS MARKET: BY ROUTE OF ADMINISTRATION, 2022 102
FIGURE 32 ASIA-PACIFIC BIOLOGICS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 103
FIGURE 33 ASIA-PACIFIC BIOLOGICS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 103
FIGURE 34 ASIA-PACIFIC BIOLOGICS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 104
FIGURE 35 ASIA-PACIFIC BIOLOGICS MARKET: BY END USER, 2022 107
FIGURE 36 ASIA-PACIFIC BIOLOGICS MARKET: BY END USER, 2023-2030 (USD MILLION) 108
FIGURE 37 ASIA-PACIFIC BIOLOGICS MARKET: BY END USER, CAGR (2023-2030) 108
FIGURE 38 ASIA-PACIFIC BIOLOGICS MARKET: BY END USER, LIFELINE CURVE 109
FIGURE 39 ASIA-PACIFIC BIOLOGICS MARKET: BY DISTRIBUTION CHANNEL, 2022 113
FIGURE 40 ASIA-PACIFIC BIOLOGICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 114
FIGURE 41 ASIA-PACIFIC BIOLOGICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 114
FIGURE 42 ASIA-PACIFIC BIOLOGICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 115
FIGURE 43 ASIA-PACIFIC BIOLOGICS MARKET: SNAPSHOT (2022) 117
FIGURE 44 ASIA-PACIFIC BIOLOGICS MARKET: BY COUNTRY (2022) 119
FIGURE 45 ASIA-PACIFIC BIOLOGICS MARKET: BY COUNTRY (2023 & 2030) 119
FIGURE 46 ASIA-PACIFIC BIOLOGICS MARKET: BY COUNTRY (2022 & 2030) 120
FIGURE 47 ASIA-PACIFIC BIOLOGICS MARKET: BY CLASS (2023-2030) 120
FIGURE 48 ASIA-PACIFIC BIOLOGICS MARKET: COMPANY SHARE 2022 (%) 180